Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06453460 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Study title shortened, about 8 words Eligibility criteria shortened, about 5 wordsv4 Show 1 more changeShow less
    • Eligibility criteria shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  3. Re-verified, no change to tracked fieldsv3
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 2024 to Jun 27, 2024 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Jun 2024 to Jun 27, 2024
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 2, prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel (CMV-TCIP) assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serology positive donor.
Trial Details
NCT Number NCT06453460
Lead Sponsor University of California, Irvine
Collaborators: Eurofins Viracor
Conditions CMV, Allogeneic Stem Cell Transplantation
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov